{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:00:41Z","timestamp":1785765641310,"version":"3.56.0"},"reference-count":63,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: to compare and characterize the frequency and severity of treatment-related adverse events (TRAEs) experienced by pediatric and adult patients with medulloblastoma receiving the same pediatric-based treatments. Methods: a retrospective comparative study of TRAEs was conducted on 18 adult patients and 45 pediatric patients with medulloblastoma treated at the same institution with craniospinal\/local radiotherapy and chemotherapy delivered according to pediatric regimens (i.e., PNET3, PNET4, PNET5 or high-risk protocols). Results: Grade \u2265 3 hematological TRAEs were significantly more frequent in adults (61.1% vs. 33.3%, p = 0.038). Adults also more frequently suffered from weight loss &gt; 10% than children (72.2% vs. 40%, p = 0.018). The incidence of chemotherapy-induced peripheral neuropathy did not differ significantly between the two groups (27.7% in adults versus 22.2% in children, p = 0.65). These findings suggest that adult patients treated with pediatric-derived protocols may benefit from more proactive hematologic and nutritional supportive care to safely maintain treatment intensity. Objective severe ototoxicity was 22.2% and 17.8% in adults and children (p = 0.69), respectively. There were significantly more adults than children who needed a dose reduction (55.6% vs. 28.9% in children, p = 0.042) and who stopped treatment prematurely (44.4% vs. 20.1% in children, p = 0.048). There was no difference in 5-year overall survival between adults and the pediatric population (88.8% vs. 86.7%, p = 0.82). Conclusions: Adults are at an increased risk of hematological and nutritional toxicities when treated for medulloblastoma with identical treatment regimens. These age-related patterns of sensitivity demand protocol modifications (such as more supportive care, nutritional support, and possibly lower dose intensities). Although there were more treatment modifications due to more severe toxicity, adults had the same survival rates as children, suggesting pediatric-based protocols should still be employed with modifications to supportive care.<\/jats:p>","DOI":"10.3390\/jcm15156023","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:57:56Z","timestamp":1785761876000},"page":"6023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Age-Dependent Toxicity Patterns in Medulloblastoma: A Comparative Analysis of Treatment-Related Adverse Events Between Pediatric and Adult Populations"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6052-3511","authenticated-orcid":false,"given":"Antonio","family":"Ruggiero","sequence":"first","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Department of Women and Child Health and Public Health, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7038-3519","authenticated-orcid":false,"given":"Dario","family":"Talloa","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Romano","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palma","family":"Maurizi","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Department of Women and Child Health and Public Health, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mastrangelo","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Department of Women and Child Health and Public Health, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8094-2847","authenticated-orcid":false,"given":"Tommaso","family":"Verdolotti","sequence":"additional","affiliation":[{"name":"ARC Advanced Radiology Center (ARC), Department of Oncological Radiotherapy and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mariani","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Radiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Chiesa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Institute of Radiology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"di Bonaventura","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Department of Neurosciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3088-0822","authenticated-orcid":false,"given":"Luca","family":"Massimi","sequence":"additional","affiliation":[{"name":"Pediatric Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Neurosurgery, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"Tamburrini","sequence":"additional","affiliation":[{"name":"Pediatric Neurosurgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Department of Neuroscience, Section of Neurosurgery, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Albanese","sequence":"additional","affiliation":[{"name":"Neurosurgery Unit, Department of Neurosciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Neurosurgery Unit, Department of Neurosciences, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9053-8765","authenticated-orcid":false,"given":"Giorgio","family":"Attin\u00e0","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016\u20132020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro-Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.32604\/or.2025.067948","article-title":"Outcomes and Toxicity of Adult Medulloblastoma Treated with Pediatric Multimodal Protocols: A Single-Institution Experience","volume":"33","author":"Ruggiero","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2006.06.4980","article-title":"Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"24","author":"Packer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1200\/JCO.2016.67.2428","article-title":"Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters","volume":"34","author":"Kortmann","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ejca.2012.10.006","article-title":"Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: A prospective observational multicentre study","volume":"49","author":"Friedrich","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/neuonc\/nox155","article-title":"Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)","volume":"20","author":"Beier","year":"2018","journal-title":"Neuro-Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.20.02730","article-title":"Children\u2019s Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma","volume":"39","author":"Michalski","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1016\/S1470-2045(19)30669-2","article-title":"EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma","volume":"20","author":"Franceschi","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1200\/JCO.2009.25.7121","article-title":"Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification","volume":"28","author":"Korshunov","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.ejca.2005.02.022","article-title":"Survival of adults treated for medulloblastoma using paediatric protocols","volume":"41","author":"Spreafico","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Franceschi, E., Minichillo, S., Mura, A., Tosoni, A., Mascarin, M., Tomasello, C., Bartolini, S., and Brandes, A.A. (2020). Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: A long term study. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07237-x"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/j.wneu.2022.04.004","article-title":"The Role of Chemotherapy in the Treatment of Adult Medulloblastoma","volume":"163","author":"Chen","year":"2022","journal-title":"World Neurosurg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1002\/cncr.21003","article-title":"Medulloblastoma in the second decade of life: A specific group with respect to toxicity and management: A Canadian Pediatric Brain Tumor Consortium Study","volume":"103","author":"Tabori","year":"2005","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25392","DOI":"10.3390\/ijms161025392","article-title":"Changes in Regenerative Capacity through Lifespan","volume":"16","author":"Yun","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bbi.2023.10.013","article-title":"More than a small adult brain: Lessons from chemotherapy-induced cognitive impairment for modelling paediatric brain disorders","volume":"115","author":"Davies","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.neuchi.2018.10.007","article-title":"Medulloblastomas in adolescents and adults\u2014Can the pediatric experience be extrapolated?","volume":"67","author":"Frappaz","year":"2021","journal-title":"Neurochirurgie"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00401-021-02358-4","article-title":"Subgroup and subtype-specific outcomes in adult medulloblastoma","volume":"142","author":"Coltin","year":"2021","journal-title":"Acta Neuropathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103866","DOI":"10.1016\/j.clon.2025.103866","article-title":"Feasibility and Outcomes of Craniospinal Irradiation and Concurrent Daily Carboplatin in Children and Adults With High-Risk Central Nervous System Tumours","volume":"44","author":"Singer","year":"2025","journal-title":"Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-015-1833-y","article-title":"Adult Medulloblastoma: Clinical Characters, Prognostic Factors, Outcomes and Patterns of Relapse","volume":"124","author":"Zhang","year":"2015","journal-title":"J. Neurooncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hau, P., Frappaz, D., Hovey, E., McCabe, M.G., Pajtler, K.W., Wiestler, B., Seidel, C., Combs, S.E., Dirven, L., and Klein, M. (2021). Development of Randomized Trials in Adults with Medulloblastoma\u2014The Example of EORTC 1634-BTG\/NOA-23. Cancers, 13.","DOI":"10.3390\/cancers13143451"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S1470-2045(20)30070-X","article-title":"Cerebrospinal Fluid Evaluation in Adult Patients with Medulloblastoma","volume":"21","author":"Hagel","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30189","DOI":"10.18632\/oncotarget.23773","article-title":"Comparing children and adults with medulloblastoma: A SEER based analysis","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/COC.0b013e31826b9cf0","article-title":"Long-term outcomes and role of chemotherapy in adults with newly diagnosed medulloblastoma","volume":"37","author":"Call","year":"2014","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bonifacio-Mundaca, J., Casavilca-Zambrano, S., Desterke, C., Casafont, \u00cd., and Mata-Garrido, J. (2025). Deciphering Medulloblastoma: Epigenetic and Metabolic Changes Driving Tumorigenesis and Treatment Outcomes. Biomedicines, 13.","DOI":"10.3390\/biomedicines13081898"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00401-012-0958-8","article-title":"Molecular subgroups of medulloblastoma: An international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas","volume":"123","author":"Kool","year":"2012","journal-title":"Acta Neuropathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00401-023-02566-0","article-title":"Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification","volume":"145","author":"Goddard","year":"2023","journal-title":"Acta Neuropathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature11213","article-title":"Novel mutations target distinct subgroups of medulloblastoma","volume":"488","author":"Robinson","year":"2012","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.31557\/APJCP.2025.26.7.2569","article-title":"Development and clinical validation of molecular subgrouping in medulloblastoma by targeted methylation sequencing","volume":"26","author":"Srivastava","year":"2025","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4103\/ijc.IJC_134_21","article-title":"The impact of nutritional status on treatment-related toxicities in children with embryonal brain tumors: The need for proactive nutritional management","volume":"61","author":"Prasad","year":"2024","journal-title":"Indian J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","article-title":"Intertumoral heterogeneity within medulloblastoma subgroups","volume":"31","author":"Cavalli","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/jayao.2024.0044","article-title":"Treatment of medulloblastoma in the adolescent and young adult population: A systematic review","volume":"14","author":"Otth","year":"2025","journal-title":"J. Adolesc. Young Adult Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/pbc.25009","article-title":"Tandem high-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuro-ectodermic tumors","volume":"61","author":"Dufour","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/noaa301","article-title":"Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5","volume":"23","author":"Dufour","year":"2021","journal-title":"Neuro-Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mushtaq, N., Ul Ain, R., Hamid, S.A., and Bouffet, E. (2023). Evolution of Systemic Therapy in Medulloblastoma Including Irradiation-Sparing Approaches. Diagnostics, 13.","DOI":"10.3390\/diagnostics13243680"},{"key":"ref_36","first-page":"245385","article-title":"Metastatic medulloblastoma in childhood: Chang\u2019s classification revisited","volume":"2012","author":"Dufour","year":"2012","journal-title":"Int. J. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13014-025-02632-9","article-title":"Impact of radiation response on survival in pediatric medulloblastoma with residual or disseminated disease","volume":"20","author":"Shi","year":"2025","journal-title":"Radiat. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"ref_40","unstructured":"US Department of Health and Human Services (2017). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000442435","article-title":"Audiological monitoring in children treated with platinum chemotherapy","volume":"21","author":"Fetoni","year":"2016","journal-title":"Audiol. Neurootol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1200\/JCO.2011.39.1110","article-title":"Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale","volume":"30","author":"Brock","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Rose, O., Croonenberg, T., Clemens, S., Hinteregger, T., Eppacher, S., Huber-Cantonati, P., Garcia-Miralles, M., Liuni, R., and Dossena, S. (2024). Cisplatin-induced hearing loss, oxidative stress, and antioxidants as a therapeutic strategy\u2014A state-of-the-art review. Antioxidants, 13.","DOI":"10.3390\/antiox13121578"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.clnu.2017.06.017","article-title":"ESPEN expert group recommendations for action against cancer-related malnutrition","volume":"36","author":"Arends","year":"2017","journal-title":"Clin. Nutr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/neuonc\/nov185","article-title":"Chemotherapy increases long-term survival in patients with adult medulloblastoma\u2014A literature-based meta-analysis","volume":"18","author":"Kocakaya","year":"2016","journal-title":"Neuro-Oncol."},{"key":"ref_46","first-page":"1757","article-title":"Postoperative evaluation for disseminated medulloblastoma involving the spine: Contrast-enhanced MR findings, CSF cytologic analysis, timing of disease occurrence, and patient outcomes","volume":"21","author":"Meyers","year":"2000","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro-Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2016.09.023","article-title":"Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study","volume":"69","author":"Clemens","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","article-title":"The importance of dose intensity in chemotherapy of metastatic breast cancer","volume":"2","author":"Hryniuk","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1007\/s12325-025-03358-6","article-title":"A Review of the Utilization of Relative Dose Intensity and Dose Delay Factor in Health Technology Appraisals of Oncology Drugs in Solid Tumors","volume":"42","author":"Dasgupta","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature02626","article-title":"Moving towards individualized medicine with pharmacogenomics","volume":"429","author":"Evans","year":"2004","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/0148607109341804","article-title":"ASPEN clinical guidelines: Nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation","volume":"33","author":"August","year":"2009","journal-title":"J. Parenter. Enter. Nutr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00401-011-0800-8","article-title":"Medulloblastoma: Clinicopathological correlates of SHH, WNT, and non-SHH\/WNT molecular subgroups","volume":"121","author":"Ellison","year":"2011","journal-title":"Acta Neuropathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrclinonc.2011.95","article-title":"Challenging issues in pediatric oncology","volume":"8","author":"Pui","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/502454","article-title":"Candida parapsilosis bloodstream infection in pediatric oncology patients: Results of an epidemiologic investigation","volume":"25","author":"Posteraro","year":"2004","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1470-2045(04)01507-4","article-title":"Late neurocognitive sequelae in survivors of brain tumours in childhood","volume":"5","author":"Mulhern","year":"2004","journal-title":"Lancet Oncol."},{"key":"ref_57","first-page":"569","article-title":"Safety and efficacy of fentanyl administered by patient controlled analgesia in children with cancer pain","volume":"15","author":"Ruggiero","year":"2007","journal-title":"Support. Care Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-009-9927-z","article-title":"From childhood to adulthood: Long-term outcome of medulloblastoma patients. The Institut Curie experience (1980\u20132000)","volume":"95","author":"Frange","year":"2009","journal-title":"J. Neurooncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-016-1569-6","article-title":"Risk stratification of childhood medulloblastoma in the molecular era: The current consensus","volume":"131","author":"Ramaswamy","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccr.2014.02.009","article-title":"Pemetrexed and gemcitabine as combination therapy for the treatment of Group 3 medulloblastoma","volume":"25","author":"Morfouace","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Talloa, D., Triarico, S., Agresti, P., Mastrangelo, S., Attin\u00e0, G., Romano, A., Maurizi, P., and Ruggiero, A. (2022). BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors. Cancers, 14.","DOI":"10.3390\/cancers14174264"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","article-title":"Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: Results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032","volume":"33","author":"Robinson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Karaulic, A., Fournier, C., and Pag\u00e8s, G. (2025). Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment. Cancers, 17.","DOI":"10.20944\/preprints202507.1627.v1"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6023\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T13:19:09Z","timestamp":1785763149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/15\/6023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":63,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15156023"],"URL":"https:\/\/doi.org\/10.3390\/jcm15156023","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}